This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Assays & screens			
Proteomic method to identify heat shock protein 90 (Hsp90)-interacting proteins as new therapeutic targets	<p>A proteomic method for identifying proteins that interact with Hsp90 in cancer cells could help identify new therapeutic targets. In a proteomic analysis of chronic myeloid leukemia (CML) cell lysates, beads labeled with the small molecule Hsp90 inhibitor PU-H71 bound to Hsp90 in complex with known oncogenic proteins and coactivator-associated arginine methyltransferase 1 (CARM1), whereas unlabeled control beads did not. In a CML cell line, small hairpin RNA-mediated knockdown of CARM1 increased apoptosis compared with that seen using scrambled shRNA controls. Next steps include using the method to identify targets in other cancers.</p> <p>PU-H71, which was identified at Memorial Sloan-Kettering Cancer Center, is in Phase I testing to treat cancer.</p> <p>SciBX 4(41); doi:10.1038/scibx.2011.1157 Published online Oct. 20, 2011</p>	Patent and licensing status unavailable	<p>Moullick, K. <i>et al. Nat. Chem. Biol.</i>; published online Sept. 25, 2011; doi:10.1038/nchembio.670 Contact: Gabriela Chiosis, Memorial Sloan-Kettering Cancer Center, New York, N.Y. e-mail: chiosisg@mskcc.org Contact: Stephen D. Nimer, same affiliation as above e-mail: nimers@mskcc.org Contact: Len Neckers, National Cancer Institute, Bethesda, Md. e-mail: neckers@nih.gov Contact: Ari Melnick, Weill Cornell Medical College, New York, N.Y. e-mail: amm2014@med.cornell.edu</p>